DOCSLIB.ORG

Successful Combination of Landiolol and Levosimendan in Patients With

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Successful Combination of Landiolol and Levosimendan in Patients With CASE REPORT Successful Combination of Landiolol and Levosimendan in Patients with Decompensated Heart Failure A Report of 3 Cases Wojciech Dabrowski,1 MD, Dorota Siwicka-Gieroba,1 MD, Ewa Piasek,1 MD, Todd T Schlegel,2,3 MD and Andrzej Jaroszynski,4 MD Summary Tachycardia and supraventricular tachyarrhythmias often impair cardiovascular capacity in patients with de- compensated heart failure (dHF) treated with inotropes. Normalization of heart rhythm or rate typically im- proves diastolic filling and stroke volume (SV). Thus, isochronal administration of an ultra-short-acting and highly selective β1-blockers, such as landiolol, along with inotropic calcium-sensitizer medications, such as levosimendan, could benefit patients with dHF. We present a case series of three patients with severe dHF and low ejection fraction who were successfully treated with a combination of landiolol and levosimendan. The co-administration of landiolol and levosimendan was well tolerated, improved cardiac function, normalized SV, and enabled the reduction of norepinephrine dos- ing in all patients. Additionally, the combination improved the vectorcardiographic spatial QRS-T angle and de- creased the corrected QT interval. All patients were successfully discharged from the intensive care unit (ICU). A combination of levosimendan and landiolol was safe and well-tolerated. This combination may be a new option for successful treatment of patients with acute dHF complicated by sinus or supraventricular tachycar- dias. (Int Heart J 2020; 61: 384-389) Key words: Critically ill, Cardiac tachyarrhthmias, Sepsis, Spatial QRS-T angle, Corrected QT interval achycardias including supraventricular tachyar- dences of atrial fibrillation and tachycardia, whereas oth- rhythmias such as atrial fibrillation are frequently ers suggest that the incidence of ventricular arrhythmias observed in patients with decompensated heart following treatment with levosimendan is no different T 1,2) 9,10) failure (dHF), increasing the risk of mortality. The de- from that with other medications used in dHF. One ex- velopment of atrial tachyarrhythmia is often associated perimental study also showed a severe proarrhythmic ef- with an irregular ventricular rhythm and an absence of an fect of levosimendan, its administration increasing the in- atrial kick, leading to a decrease in cardiac output with ducibility of life-threatening arrhythmias in a dose- consequent worsening of cardiac hemodynamic func- dependent manner.11) Levosimendan also tends to prolong tion.1-5) Therefore, the normalization of heart rhythm or the rate-corrected QT interval in healthy volunteers, al- rate can often play a crucial role in the correction of car- though such an effect has not always been observed in pa- diac dysfunction. Some of the medications frequently used tients with heart failure treated with therapeutic doses.12) in patients with dHF failure also commonly induce tachy- Therefore, some authors have suggested a combination of cardia. levosimendan and β-blockers, particularly in patients with Levosimendan is a calcium-sensitizing inotropic a tendency to tachyarrhythmia.13,14) agent that increases cardiac contractility without increas- Landiolol is a new, ultra-short-acting β1-receptor an- ing oxygen consumption.6) It also presents an anti- tagonist useful for both treatment and prevention of su- stunning and anti-ischemic effect via the opening of the praventricular tachyarrhythmias. Landiolol at the dose of KATP channels in cardiac mitochondria, potentially decreas- 1-10 μg/kg/minute is also more effective than digoxin in ing mortality.7) Levosimendan is recommended by the controlling the ventricular response rate during atrial fib- European Society of Cardiology for patients with acute rillation in patients with heart failure.15) Several studies dHF.8) However, some studies have documented that treat- have documented its beneficial effect on cardiac rhythm in ment with levosimendan is associated with higher inci- patients with severe acute heart failure and tachycar- From the 1Department of Anaesthesiology and Intensive Care Medical University of Lublin, Poland, 2Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden, 3Nicollier-Schlegel SARL, Trélex, Switzerland and 4Department of Nephrology, Institute of Medical Science, Jan Kochanowski University of Kielce, Poland. Address for correspondence: Wojciech Dabrowski, MD, Department of Anaesthesiology and Intensive Care Medical University of Lublin, Jaczewskiego 8, 20-954 Lublin, Poland. E-mail: [email protected] Received for publication August 15, 2019. Revised and accepted October 25, 2019. Released in advance online on J-STAGE March 4, 2020. doi: 10.1536/ihj.19-420 All rights reserved by the International Heart Journal Association. 384 IntHeartJ March 2020 LANDIOLOL AND LEVOSIMENDAN IN THE CRITICALLY ILL 385 dia.16-18) Landiolol restores stroke volume (SV) in septic shock and decreases stroke volume variation, probably be- cause of a decrease in the difference between maximum and minimum SV during breathing.17,18) Based on these ac- tions, we can assume that a combination of a strong inotropic agent, such as levosimendan, and the ultra- selective β1-blocker landiolol may improve cardiac hemo- dynamic function by increasing cardiac output (CO) via improved ventricular filling following the correction of heart rhythm and/or rate. In this study, we report cases of three patients treated with a combination of levosimendan and landiolol for severe shock with tachyarrhythmia. Case Reports In all cases, hemodynamic parameters were measured for all three presented patients, including this patient, us- ing an EV 1000 platform (Edwards Lifesciences, Irvine, CA, USA) that also incorporates thermodilution. Spatial QRS-T angle and corrected QT (QTc) intervals were also automatically calculated in the same patients, by using a Cardiax computerized 12-lead electrocardiographic system (IMED, Budapest, Hungary), as previously described.19) The results of all measurements for all three patients, per- formed each morning for 5 serial days, are presented in Figure 1. Case 1: A 70-year-old woman (78 kg) was admitted to the intensive care unit (ICU) with critical acute cardiac failure and left ventricular ejection fraction (LVEF) < 25% complicated by pulmonary edema. This case was included within a larger prospective observational study, performed at the First Clinic of Intensive Care at the Medical Uni- versity of Lublin, Poland (KE-0254/172/2019). Patient was mechanically ventilated with FiO2 0.7 and PEEP + 10 cmH2O. Ten days before admission to the ICU, she had undergone coronary artery bypass surgery (CABG) with extracorporeal circulation for acute coronary symptoms. Her comorbidities included hypertension and type II dia- betes. The cardiac surgery was uncomplicated, and the pa- tient required dobutamine infusion from the end of extra- corporeal circulation to the 8 postoperative hour. Doses of dobutamine were gradually reduced from 7 μg/kg/min. The postoperative period was also without serious compli- cations. A day before the admission into ICU, tachycardia with severe suffocation and rapid decrease in arterial oxy- gen tension to 58 mmHg were noted. The patient required oxygen supplementation with oxygen face-mask, and she was then intubated and mechanically ventilated with 70% of oxygen. The patient was admitted into cardiac- postoperative intensive care and received an initial dose of amiodarone at 5 mg/kg/1 hour, continuing by 0.01 mg/kg/ min. The norepinephrine infusion was started to maintain mean arterial blood pressure (MAP) between 60-70 mmHg. The treatment with amiodarone was unsuccessful. A coronary angiogram was performed just before admis- sion to ICU and the presence of important disorders in Figure 1. Changes in heart rate (HR), cardiac index (CI), stroke vol- ume index (SVI), dose of norepinephrine, and vectorcardiography blood flow were excluded. Hemodynamic measurements variables such as spatial QRS-T angle and corrected QT (QTc) interval showed low cardiac index (CI) (Figure 1) with high ex- in studied patients. The observations were made at five time points: 5 travascular water index (ELWI = 13.8 mL/kg). Systemic min before treatment with a combination of landiolol and levosimen- vascular resistance index (SVRI = 2776 dyne-s-m2/cm5) dan, and 24, 48, 72, and 96 hours after the beginning of treatment. was maintained with continuous norepinephrine infusion IntHeartJ 386 DABROWSKI, ET AL March 2020 at 0.41 μg/kg/minute, with MAP being maintained be- antibiotic therapy was started. Based on KIDIGO criteria, tween 60 and 70 mmHg. Laboratory measurements acute kidney injury with anuria was diagnosed and con- showed high plasma troponin I concentration (529 ng/L) tinuous renal replacement therapy was started. Laboratory and N-terminal fragment of prohormone B-type natriuretic studies showed high plasma procalcitonin concentration peptide (Nt-proBNP = 14,931 pg/mL). Immediately after (PCT = 32 ng/mL), high Nt-proBNP (6520 pg/mL), and admission to the ICU, the patient received an intravenous leukocytosis (WBC = 17,200/mL). Transthoracic echocar- infusion of dobutamine at 9 μg/kg/minute. The dobu- diography showed global impaired cardiac contractility tamine infusion did not improve CI, but increased tachyar- with an LVEF of ~20%. Based on clinical symptoms and rhythmia. Diuresis was maintained by continuous fu- hemodynamic findings, intravenous infusion of levosimen- rosemide (Furosemide, Polfa, Pl) infusion
Load more

Recommended publications
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • A Framework for Assurance of Medication Safety Using Machine Learning
    A Framework for Assurance of Medication Safety using Machine Learning Yan Jia1 Tom Lawton2 John McDermid1 Eric Rojas3 Ibrahim Habli1 Abstract— Medication errors continue to be the leading cause of avoidable patient harm in hospitals. This paper sets out a framework to assure medication safety that combines machine learning and safety engineering methods. It uses safety analysis to proactively identify potential causes of medication error, based on expert opinion. As healthcare is now data rich, it is possible to augment safety analysis with machine learning to discover actual causes of medication error from the data, and to identify where they deviate from what was predicted in the safety analysis. Combining these two views has the potential to enable the risk of medication errors to be managed proactively and dynamically. We apply the framework to a case study involving thoracic surgery, e.g. oesophagectomy, where errors in giving beta-blockers can be critical to control atrial fibrillation. This case study combines a HAZOP-based safety analysis method known as SHARD with Bayesian network structure learning and process mining to produce the analysis results, showing the potential of the framework for ensuring patient safety, and for transforming the way that safety is managed in complex healthcare environments. Keywords—medication safety, machine learning, proactive safety management 1. INTRODUCTION Safety analysis is both predictive and reactive. It aims to identify hazards, hazard causes and mitigations, and associated risks before a system is deployed. The system is then monitored during its deployment to manage risks. When systems are used in highly controlled environments, built using components with a long service history, these predictions can be accurate.
    [Show full text]
  • Annual Report 2016
    Annexes to the annual report of the European Medicines Agency 2016 Annex 1 – Members of the Management Board ............................................................... 2 Annex 2 - Members of the Committee for Medicinal Products for Human Use ...................... 4 Annex 3 – Members of the Pharmacovigilance Risk Assessment Committee ........................ 6 Annex 4 – Members of the Committee for Medicinal Products for Veterinary Use ................. 8 Annex 5 – Members of the Committee on Orphan Medicinal Products .............................. 10 Annex 6 – Members of the Committee on Herbal Medicinal Products ................................ 12 Annex 7 – Committee for Advanced Therapies .............................................................. 14 Annex 8 – Members of the Paediatric Committee .......................................................... 16 Annex 9 – Working parties and working groups ............................................................ 18 Annex 10 – CHMP opinions: initial evaluations and extensions of therapeutic indication ..... 24 Annex 10a – Guidelines and concept papers adopted by CHMP in 2016 ............................ 25 Annex 11 – CVMP opinions in 2016 on medicinal products for veterinary use .................... 33 Annex 11a – 2016 CVMP opinions on extensions of indication for medicinal products for veterinary use .......................................................................................................... 39 Annex 11b – Guidelines and concept papers adopted by CVMP in 2016 ...........................
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Annexes to the Annual Report of the European Medicines Agency 2014
    Annexes to the annual report of the European Medicines Agency 2014 Table of contents Annex 1 – Members of the Management Board ............................................................................. 2 Annex 2 – Members of the Committee for Medicinal Products for Human Use ................................... 4 Annex 3 – Members of the Pharmacovigilance Risk Assessment Committee ...................................... 6 Annex 4 – Members of the Committee for Medicinal Products for Veterinary Use ............................... 8 Annex 5 – Members of the Committee on Orphan Medicinal Products ............................................ 10 Annex 6 – Members of the Committee on Herbal Medicinal Products .............................................. 12 Annex 07 – Committee for Advanced Therapies .......................................................................... 14 Annex 8 – Members of the Paediatric Committee ........................................................................ 16 Annex 9 – Working parties and working groups .......................................................................... 18 Annex 10 – CHMP opinions in 2014 on medicinal products for human use ...................................... 22 Annex 11 – CVMP opinions in 2014 on medicinal products for veterinary use .................................. 36 Annex 12 – COMP opinions in 2014 on designation of orphan medicinal products ............................ 41 Annex 13 – HMPC European Union herbal monographs in 2014....................................................
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Peri-Operative Medicine John Cohn
    Perioperative Medicine Steven L. Cohn (Editor) Perioperative Medicine Editor Steven L. Cohn Director – Medical Consultation Service Kings County Hospital Center Clinical Professor of Medicine SUNY Downstate Brooklyn, NY ISBN 978-0-85729-497-5 e-ISBN 978-0-85729-498-2 DOI 10.1007/978-0-85729-498-2 Springer London Dordrecht Heidelberg New York British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library Library of Congress Control Number: 2011931531 © Springer-Verlag London Limited 2011 Apart from any fair dealing for the purposes of research or private study, or criticism or review, as permit- ted under the Copyright, Designs and Patents Act 1988, this publication may only be reproduced, stored or transmitted, in any form or by any means, with the prior permission in writing of the publishers, or in the case of reprographic reproduction in accordance with the terms of licenses issued by the Copyright Licensing Agency. Enquiries concerning reproduction outside those terms should be sent to the publishers. The use of registered names, trademarks, etc., in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore free for general use. Product liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature. Cover design: eStudioCalamar, Figueres/Berlin Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com) Preface Preoperative risk assessment and perioperative management are important aspects of clinical practice in internal medicine.
    [Show full text]
  • Safety and Efficacy of a Bolus Injection of Landiolol Hydrochloride As A
    Advance Publication by-J-STAGE Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Safety and Efficacy of a Bolus Injection of Landiolol Hydrochloride as a Premedication for Multidetector-Row Computed Tomography Coronary Angiography Kazuhiro Osawa, MD; Toru Miyoshi, MD; Shuhei Sato, MD; Noriaki Akagi; Yusuke Morimitsu; Kazufumi Nakamura, MD; Kunihisa Kohno, MD; Kengo Kusano, MD; Susumu Kanazawa, MD; Hiroshi Ito, MD Background: We evaluated the safety and efficacy of a bolus injection of landiolol hydrochloride, an ultrashort-act- ing β1-selective antagonist, as an additional treatment after premedication with an oral β-blocker to reduce heart rate prior to multidetector-row computed tomography (MDCT) coronary angiography (CAG). Methods and Results: A total of 458 patients who underwent MDCT CAG were retrospectively enrolled. Image quality and hemodynamic parameters were compared in patients before and after approval of landiolol hydrochloride. If heart rate reduction was insufficient after premedication with an oral β-blocker, a bolus injection of landiolol hydro- chloride (n=66) or other drugs (n=30) was used. The percentage of evaluable images per segment in patients after approval of landiolol (99.3%) was greater than that in patients before approval of landiolol (97.4%, P<0.01). Heart rates before scanning in patients receiving landiolol hydrochloride were similar to those receiving other drugs. Heart rate was significantly reduced approximately 5 min after injection of landiolol hydrochloride and increased shortly. No decrease in systolic blood pressure or other adverse effects was observed. Conclusions: Bolus injection of landiolol hydrochloride sufficiently reduced heart rate without significantly reducing systolic blood pressure and produced a high percentage of evaluable images, suggesting that bolus injection of landiolol hydrochloride as an additional pretreatment is feasible in MDCT CAG.
    [Show full text]
  • Use of Landiolol Hydrochloride in the Long-Term Treatment of Tachyarrhythmias
    (19) TZZ _¥_T (11) EP 2 796 139 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 29.10.2014 Bulletin 2014/44 A61K 31/5377 (2006.01) A61P 9/06 (2006.01) (21) Application number: 13165582.1 (22) Date of filing: 26.04.2013 (84) Designated Contracting States: (72) Inventor: Krumpl, Günther AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 1010 Vienna (AT) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Loidl, Manuela Bettina et al Designated Extension States: REDL Life Science Patent Attorneys BA ME Donau-City-Straße 11 1220 Wien (AT) (71) Applicant: AOP Orphan Pharmaceuticals AG 1160 Vienna (AT) (54) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias (57) The invention provides a new use of landiolol patient is persistently reduced during the administration hydrochloride in the treatment of a subject suffering from period compared to the heart rate before treatment and tachycardia or tachyarrhythmia, wherein landiolol- hydro- no overshooting effect occurs after termination of said chloride is administered for a period of at least 0.5 hours administration. and up to at least 2 days, wherein the heart rate of said EP 2 796 139 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 796 139 A1 Description [0001] The invention provides a new use of landiolol hydrochloride in the treatment of a subject suffering from tachy- cardia or tachyarrhythmia, wherein landiolol-hydrochloride is administered for a period of at least 0.5 hours and up to at 5 least 2 days, wherein the heart rate of said patient is persistently reduced during the administration period compared to the heart rate before treatment.
    [Show full text]
  • Drug Consumption at Wholesale Prices in 2017 - 2020
    Page 1 Drug consumption at wholesale prices in 2017 - 2020 2020 2019 2018 2017 Wholesale Hospit. Wholesale Hospit. Wholesale Hospit. Wholesale Hospit. ATC code Subgroup or chemical substance price/1000 € % price/1000 € % price/1000 € % price/1000 € % A ALIMENTARY TRACT AND METABOLISM 321 590 7 309 580 7 300 278 7 295 060 8 A01 STOMATOLOGICAL PREPARATIONS 2 090 9 1 937 7 1 910 7 2 128 8 A01A STOMATOLOGICAL PREPARATIONS 2 090 9 1 937 7 1 910 7 2 128 8 A01AA Caries prophylactic agents 663 8 611 11 619 12 1 042 11 A01AA01 sodium fluoride 610 8 557 12 498 15 787 14 A01AA03 olaflur 53 1 54 1 50 1 48 1 A01AA51 sodium fluoride, combinations - - - - 71 1 206 1 A01AB Antiinfectives for local oral treatment 1 266 10 1 101 6 1 052 6 944 6 A01AB03 chlorhexidine 930 6 885 7 825 7 706 7 A01AB11 various 335 21 216 0 227 0 238 0 A01AB22 doxycycline - - 0 100 0 100 - - A01AC Corticosteroids for local oral treatment 113 1 153 1 135 1 143 1 A01AC01 triamcinolone 113 1 153 1 135 1 143 1 A01AD Other agents for local oral treatment 49 0 72 0 104 0 - - A01AD02 benzydamine 49 0 72 0 104 0 - - A02 DRUGS FOR ACID RELATED DISORDERS 30 885 4 32 677 4 35 102 5 37 644 7 A02A ANTACIDS 3 681 1 3 565 1 3 357 1 3 385 1 A02AA Magnesium compounds 141 22 151 22 172 22 155 19 A02AA04 magnesium hydroxide 141 22 151 22 172 22 155 19 A02AD Combinations and complexes of aluminium, 3 539 0 3 414 0 3 185 0 3 231 0 calcium and magnesium compounds A02AD01 ordinary salt combinations 3 539 0 3 414 0 3 185 0 3 231 0 A02B DRUGS FOR PEPTIC ULCER AND 27 205 5 29 112 4 31 746 5 34 258 8
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Ultra-Short-Acting Beta Blockers Could Play Important Role in Minimizing Decatecholaminization
    12 ISICEM News Wednesday 21 March 2018 Issue 2 Ultra-short-acting beta blockers could play important role in minimizing decatecholaminization uring yesterday’s Amomed- evidence that perhaps we need a logical phenotype that can identify “Catecholaminergic vasopressors sponsored symposium little bit of sympathetic stimula- those patients who will benefit from may induce adverse cardiac events. D‘Decatecholaminization tion in our lives, but too much the drug. When it comes to using We need to think about the nega- What’s new?’, Matthias Heringlake, of a good thing becomes bad, beta-blockers for these patients, the tive side effects when using catecho- Professor of Anesthesiology at the and unfortunately once a patient single-center trial from Morelli et lamines and consider alternatives University of Lübeck, Germany becomes ill we then ply them with al. in patients with resistant septic – one possibility being vasopressin.” and Johann Knotzer, Head of the even more stimulation in the form shock showed that esmolol was Vasopressin works in the Department of Anesthesiology at of catecholamines.” effective in reducing heart rate to endothelium mainly through VI: Hospital Wels-Grieskirchen, Aus- “Alternatives include vasopres- target levels without an increase “Relative vasopressin deficiency tria, spoke about the role of ultra- sin, but the clinical trials conducted in adverse outcomes compared to backs up the rationale for early- short-acting beta blockers in sepsis, so far have not shown any differ- standard treatment, and that out- phase combinations of vasopres- and after cardiac surgery. ence in outcomes, although a recent comes, including time on vasopres- sin and norepinephrine in cardiac Managing septic shock remains post-hoc analysis of the VASST sors and mortality, were improved.2 surgery patients,” said Dr Knotzer.
    [Show full text]